Evolus Inc
$ 7.59
2.43%
07 Aug - close price
- Market Cap 501,323,000 USD
- Current Price $ 7.59
- High / Low $ 7.80 / 7.21
- Stock P/E N/A
- Book Value -0.47
- EPS -0.53
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -187.30 %
- 52 Week High 7.95
- 52 Week Low 3.86
About
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Analyst Target Price
$14.67
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-04 | 2026-03-03 | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-03-04 | 2024-11-06 | 2024-07-31 | 2024-05-07 | 2024-03-07 | 2023-11-07 |
| Reported EPS | -0.09 | -0.05 | 0.0132 | -0.2 | -0.26 | -0.17 | 0.0139 | -0.18 | -0.06 | -0.11 | -0.12 | -0.18 |
| Estimated EPS | -0.09 | -0.12 | 0.0373 | -0.26 | -0.09 | -0.14 | 0.0223 | -0.11 | -0.06 | -0.08 | -0.07 | -0.18 |
| Surprise | 0 | 0.07 | -0.0241 | 0.06 | -0.17 | -0.03 | -0.0084 | -0.07 | 0 | -0.03 | -0.05 | 0 |
| Surprise Percentage | 0% | 58.3333% | -64.6113% | 23.0769% | -188.8889% | -21.4286% | -37.6682% | -63.6364% | 0% | -37.5% | -71.4286% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EOLS
2026-08-06 23:41:02
Evolus, Inc. reported strong Q2 earnings with double-digit revenue growth and a third consecutive quarter of positive adjusted EBITDA, driven by its toxin franchise and growing international presence. Despite increased operating expenses and tariff uncertainty, the company raised its 2026 revenue guidance and reaffirmed long-term targets, signaling a confident outlook for profitable expansion. The company emphasized portfolio diversification and strategic investments, including a new skin quality licensing deal, as key drivers for future growth.
2026-08-06 16:41:02
This article provides a compilation of recent news, articles, and updates concerning Evolus Inc (EOLS). Key highlights include Evolus reporting strong Q2 2026 financial results with positive adjusted EBITDA, expanding partnerships, and announcing future earnings report dates. The company also reported inducement grants of restricted stock units and a significant partnership with IBSA to develop and commercialize Profhilo in the US.
2026-08-06 00:16:13
Evolus, Inc. (EOLS) reported break-even quarterly earnings per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also exceeded revenue expectations, posting $84.08 million against an estimated $82.02 million. Despite outperforming earnings estimates three out of the last four quarters and revenue estimates consistently, Evolus's stock has lost 8% year-to-date, contrasting with the S&P 500's 13% gain.
2026-08-05 22:03:21
Evolus Inc. reported strong Q2 2026 results, with revenue up 21% year-over-year to $84.1 million, marking its third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 revenue guidance to $330-$337 million and reaffirmed its long-term target of $450-$500 million by 2028, driven by its expanding portfolio of aesthetic injectables and a digital-first customer engagement strategy. Despite a wider-than-expected adjusted loss per share, investors reacted positively to the revenue beat and improved outlook, as Evolus transitions from a single-product business to a diversified aesthetics platform.
2026-08-05 21:02:00
Evolus (EOLS) reported strong Q2 2026 earnings, with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding analyst estimates. The company also improved its financial performance by narrowing its operating and net losses. Insider trading activity showed sales by executives, while institutional investors had mixed movements in their holdings.
2026-08-05 20:16:13
Evolus (NASDAQ: EOLS) reported strong Q2 2026 financial results with net revenue of $84.1 million, a 21% increase year-over-year, and positive adjusted EBITDA of $4.7 million. This marks the third consecutive quarter of positive adjusted EBITDA for the company. Consequently, Evolus has raised its full-year 2026 net revenue guidance to between $330 million and $337 million and its adjusted gross profit margin guidance to 67.0% to 67.5%, while reaffirming its 2028 long-term financial outlook.
